Chemomab Therapeutics (CMMB)
(Delayed Data from NSDQ)
$0.67 USD
+0.01 (0.75%)
Updated Apr 23, 2024 04:00 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
Income Statements
Fiscal Year end for Chemomab Therapeutics Ltd Sponsored ADR falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 25 | 29 | 12 | 12 | 23 |
Income After Depreciation & Amortization | -25 | -29 | -12 | -12 | -23 |
Non-Operating Income | 1 | 0 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 4 |
Pretax Income | -24 | -28 | -12 | -12 | -27 |
Income Taxes | 0 | -1 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -24 | -28 | -12 | -12 | -27 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -24 | -28 | -12 | -12 | -27 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -25 | -28 | -12 | -12 | -23 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -25 | -29 | -12 | -12 | -23 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 11.75 | 11.38 | 10.37 | 0.46 | 0.43 |
Diluted EPS Before Non-Recurring Items | -2.06 | -2.42 | -1.20 | -23.68 | -55.36 |
Diluted Net EPS (GAAP) | -2.06 | -2.42 | -1.20 | -25.04 | -63.20 |
Fiscal Year end for Chemomab Therapeutics Ltd Sponsored ADR falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 3.85 | 4.37 | 8.20 | 9.05 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -3.85 | -4.37 | -8.20 | -9.05 |
Non-Operating Income | NA | 0.69 | 0.23 | 0.00 | 0.32 |
Interest Expense | NA | 0.26 | 0.00 | -0.26 | 0.00 |
Pretax Income | NA | -3.42 | -4.14 | -7.94 | -8.73 |
Income Taxes | NA | 0.00 | -0.06 | 0.03 | 0.02 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -3.42 | -4.08 | -7.97 | -8.75 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -3.42 | -4.08 | -7.97 | -8.75 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 13.01 | 11.82 | 11.08 | 11.41 |
Diluted EPS Before Non-Recurring Items | NA | -0.26 | -0.34 | -0.72 | -0.80 |
Diluted Net EPS (GAAP) | NA | -0.21 | -0.34 | -0.72 | -0.79 |